Respiri on verge of negotiating ground-breaking China partnership
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Developer and distributor of devices to improve the management of chronic and costly respiratory disorders such as asthma and COPD, Respiri (ASX:RSH) has announced that it is on the verge of establishing a partnership vehicle to manufacture and market an updated AirSonea device in China.
In updating the market on the status of discussions, management said, “Respiri confirms it has received a written, commercial-in-confidence draft proposal to establish a partnership vehicle to manufacture and market an updated AirSonea in China.”
AirSonea is RSH’s flagship product, providing users with the ability to self-manage their conditions with the aid of smart phones, including a connected device for nocturnal monitoring which is in development.
These products have been cleared for use by the US FDA, the European Union CE and the Australian TGA. RSH has begun the approval process required for introduction into Asian markets.
The company had recently flagged the possibility of a partnership agreement with one or more parties in China, sparking a circa 20% share price rerating. Consequently, today’s news has had little impact on the company’s share price, with investors perhaps viewing the news as being already factored in.
Of course it should be noted that share trading patterns should not be used as the basis for an investment as they may or may not be replicated. Those considering this stock should seek independent financial advice.
However, the significance of such an agreement can’t be understated as China has approximately 100 million asthma sufferers, including millions of children. It is the leading cause of children’s hospitalisation and imposes a significant burden on families and the China health system.
Consequently, such an agreement could open up a huge addressable market, and there is the potential in a country that is struggling to keep abreast of this common issue, for government support perhaps in terms of assisting in the funding of development and/or opening up channels of distribution.
However, aside from that the Chinese market represents a significant opportunity as rapid economic growth and urbanisation continues to cause increased prevalence of asthma and other respiratory diseases.
Asthma education and management control in China remains poor and it has the world’s highest mortality rate.
The living environment itself is so challenging that using devices to manage the associated problems will be ongoing with demand increasing as population and industrialisation escalates.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.